Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Linical Co., Ltd. ( (JP:2183) ) just unveiled an update.
Linical Co., Ltd. has revised its consolidated financial forecast for the fiscal year ending March 2025 due to underperformance in new project acquisitions and project delays across Japan, South Korea, Europe, and the United States. Despite the forecasted downturn, Linical has recorded a gain of 107 million yen from income tax adjustments and maintains its dividend forecast, highlighting its commitment to balancing corporate growth and shareholder returns.
More about Linical Co., Ltd.
Linical Co., Ltd. operates within the pharmaceutical and clinical research industry, focusing on providing clinical development solutions. The company serves a global market, including regions such as Japan, South Korea, Europe, and the United States.
Average Trading Volume: 48,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.86B
See more data about 2183 stock on TipRanks’ Stock Analysis page.